Jefferies Downgrades Caliper Life Sciences (CALP) to Hold

Jefferies downgraded Caliper Life Sciences (NASDAQ: CALP) from Buy to Hold with a price target of $10.50 after PerkinElmer Inc. (PKI) takeover.

The firm comments, "PKI will acquire CALP for ~$600M ($10.50/share), which implies an enterprise value of ~3.5 times next-12-month revenue forecasts. Our price target moves to $10.50 (from $10) to reflect our belief in a successful close. Given the stock's close proximity to the proposed transaction price, we are lowering our rating to Hold (from Buy)."

For more ratings news on Caliper Life Sciences click here and for the rating history of Caliper Life Sciences click here.

Shares of Caliper Life Sciences closed at $10.45 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Downgrades Enphase Energy (ENPH) to Hold, 'Still Muddling Through'
• HSBC Downgrades Anglo American Platinum Limited (AMS:SJ) (ANGPY) to Reduce
• Jefferies Downgrades Calix (CALX) to Hold